Liver Infarction after Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma in the Setting of a Large Portosystemic Shunt

Benjamin V. Park; Ron C. Gaba; R. Peter Lokken

doi:10.1055/s-0036-1592319

Seminars in Interventional Radiology, Table of Contents

Semin intervent Radiol 2016; 33(04): 337-341
DOI: 10.1055/s-0036-1592319

Morbidity & Mortality

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Liver Infarction after Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma in the Setting of a Large Portosystemic Shunt

Authors

Benjamin V. Park

¹Department of Radiology, University of Illinois Hospital and Health Sciences System, Chicago, Illinois
Ron C. Gaba

¹Department of Radiology, University of Illinois Hospital and Health Sciences System, Chicago, Illinois
R. Peter Lokken

¹Department of Radiology, University of Illinois Hospital and Health Sciences System, Chicago, Illinois

Abstract

Full Text

References

References
1 Bruix J, Sherman M ; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (3) 1020-1022
2 Tarazov PG, Polysalov VN, Prozorovskij KV, Grishchenkova IV, Rozengauz EV. Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol 2000; 41 (2) 156-160
3 Fujiwara H, Kanazawa S, Hiraki T , et al. Hepatic infarction following abdominal interventional procedures. Acta Med Okayama 2004; 58 (2) 97-106
4 Raoul JL, Sangro B, Forner A , et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37 (3) 212-220
5 A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med 1995; 332 (19) 1256-1261
6 Garwood ER, Fidelman N, Hoch SE, Kerlan Jr RK, Yao FY. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl 2013; 19 (2) 164-173
7 Hsin IF, Hsu CY, Huang HC , et al. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction. J Clin Gastroenterol 2011; 45 (6) 556-562
8 Boulin M, Adam H, Guiu B , et al. Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma. Dig Liver Dis 2014; 46 (4) 358-362
9 Bouvier A, Ozenne V, Aubé C , et al. Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 2011; 21 (8) 1719-1726
10 Jin B, Wang D, Lewandowski RJ , et al. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol 2011; 196 (4) 919-928
11 Tesdal IK, Wikström M, Flechtenmacher C, Filser T, Dueber C. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. Cardiovasc Intervent Radiol 2006; 29 (5) 778-784
12 Kang JW, Kim JH, Ko GY, Gwon DI, Yoon HK, Sung KB. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol 2012; 53 (5) 545-550
13 Wang Z, Zhang H, Zhao H , et al. Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Diagn Interv Radiol 2014; 20 (6) 487-491
14 Miura JT, Rilling WS, White SB , et al. Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. HPB (Oxford) 2015; 17 (8) 707-712
15 Kohi MP, Fidelman N, Naeger DM, LaBerge JM, Gordon RL, Kerlan Jr RK. Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong?. J Vasc Interv Radiol 2013; 24 (1) 68-73
16 Gaba RC, Rim CM, Parvinian A. Re: Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong?. J Vasc Interv Radiol 2013; 24 (7) 1075-1076
17 Lammer J, Malagari K, Vogl T , et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (1) 41-52
18 van Malenstein H, Maleux G, Vandecaveye V , et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34 (7) 368-376
19 Gorodetski B, Chapiro J, Schernthaner R , et al. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 2016;
20 Kuo YC, Kohi MP, Naeger DM , et al. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 2013; 36 (5) 1336-1343
21 Padia SA, Chewning RH, Kogut MJ , et al. Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts. Cardiovasc Intervent Radiol 2015; 38 (4) 913-921
22 Park JK, Al-Tariq QZ, Zaw TM, Raman SS, Lu DS. Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts. Cardiovasc Intervent Radiol 2015; 38 (5) 1211-1217
23 Donahue LA, Kulik L, Baker T , et al. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2013; 24 (1) 74-80